丝氨酸蛋白酶HTRA1作为原发性膜性肾病的新靶抗原
研究采用免疫印迹、免疫沉淀、质谱、激光捕获显微切割和蛋白片段微阵列等多技术,在部分原发性膜性肾病患者中鉴定出丝氨酸蛋白酶HTRA1为新型足细胞抗原。抗HTRA1抗体以IgG4为主,活动期滴度显著高于缓解期,在118例四阴性患者中患病率为4.2%。
要点
- HTRA1是原发性膜性肾病的新型靶抗原,抗体以IgG4为主。
- 在四阴性(PLA2R、THSD7A、NELL1、EXT2阴性)患者中HTRA1相关患病率为4.2%。
- 抗HTRA1抗体滴度可能随疾病活动度变化。
核心结论
- 丝氨酸蛋白酶HTRA1被鉴定为原发性膜性肾病的靶抗原。
研究设计与样本
- 采用免疫印迹、免疫沉淀、质谱、激光捕获显微切割、免疫复合物洗脱和蛋白片段微阵列等多技术方法。
- 在三个队列中鉴定出14例HTRA1相关膜性肾病患者。
- 筛查118例四阴性(PLA2R-、THSD7A-、NELL1-、EXT2-)患者。
主要发现
- 两名患者血清在还原和非还原条件下与51-kD肾小球提取物蛋白及重组人HTRA1反应。
- 抗HTRA1抗体主要为IgG4,提示原发性病因。
- 活动期血清抗HTRA1抗体滴度显著高于缓解期。
- 在118例四阴性患者中HTRA1相关膜性肾病患病率为4.2%。
关键数值与推荐
- 四阴性患者中HTRA1相关患病率为4.2%。
- 抗HTRA1抗体主要为IgG4。
- 免疫印迹检测到51-kD蛋白。
临床怎么用
- 对传统靶抗原阴性的原发性膜性肾病患者可考虑检测抗HTRA1抗体。
- 抗HTRA1抗体滴度可能用于监测疾病活动度。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identification of target antigens PLA2R, THSD7A, NELL1, or Semaphorin-3B can explain the majority of cases of primary membranous nephropathy (MN). However, target antigens remain unidentified in 15%-20% of patients. METHODS: A multipronged approach, using traditional and modern technologies, converged on a novel target antigen, and capitalized on the temporal variation in autoantibody titer for biomarker discovery. Immunoblotting of human glomerular proteins followed by differential immunoprecipitation and mass spectrometric analysis was complemented by laser-capture microdissection followed by mass spectrometry, elution of immune complexes from renal biopsy specimen tissue, and autoimmune profiling on a protein fragment microarray. RESULTS: These approaches identified serine protease HTRA1 as a novel podocyte antigen in a subset of patients with primary MN. Sera from two patients reacted by immunoblotting with a 51-kD protein within glomerular extract and with recombinant human HTRA1, under reducing and nonreducing conditions. Longitudinal serum samples from these patients seemed to correlate with clinical disease activity. As in PLA2R- and THSD7A- associated MN, anti-HTRA1 antibodies were predominantly IgG4, suggesting a primary etiology. Analysis of sera collected during active disease versus remission on protein fragment microarrays detected significantly higher titers of anti-HTRA1 antibody in active disease. HTRA1 was specifically detected within immune deposits of HTRA1-associated MN in 14 patients identified among three cohorts. Screening of 118 "quadruple-negative" (PLA2R-, THSD7A-, NELL1-, EXT2-negative) patients in a large repository of MN biopsy specimens revealed a prevalence of 4.2%. CONCLUSIONS: Conventional and more modern techniques converged to identify serine protease HTRA1 as a target antigen in MN.
引用
- Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy. J Am Soc Nephrol. 2021. PMID: 33952630. doi:10.1681/ASN.2020101395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。